Merck boosts late-phase cancer pipeline with $1.1B Peloton buy

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 21, 2019 at 9:42 AM.

  1. #1 cafead, May 21, 2019 at 9:42 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via Merck has struck a deal to buy Peloton Therapeutics for $1.1 billion upfront days before the biotech was due to list on Nasdaq. The deal will give Merck control of an experimental oral HIF-2α inhibitor that could challenge Keytruda for the metastatic renal cell carcinoma (mRCC) market.

    article source
     
    Quote

Reply to Thread